Phase I evaluation of IMPY in a twice weekly schedule.
IMPY was given to 25 patients with advanced cancer on a twice weekly schedule in escalating doses from 165 to 3000 mg/m2. Nausea, vomiting, fatigue, generalized weakness, and decreases in performance status were dose-limiting. In one patient treated at a dose of 3000 mg/m2 for three doses, hemolytic anemia resulted, with a 6-g/dl decrease in hemoglobin. No tumor regression occurred. A reasonable starting dose for phase II studies is 1200 mg/m2 twice weekly for 3 weeks, with planned rapid escalation to 1800 mg/m2 in patients tolerating the lower dose level.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy*; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D007093:Imidazoles; D011720:Pyrazoles; C000971:2,3-dihydro-1H-imidazo(1,2-b)pyrazole